Answers are grounded in this paper and cite their sources.
Background: Dissemination makes prostate cancer lethal, and few therapies target it directly. Integrin alpha-6 (ITGA6) is a laminin-binding receptor cleaved by urokinase (uPA), which releases its extracellular domain and leaves a membrane-retained fragment, α6p. We hypothesized that ITGA6 and its cleavage are required for dissemination in tumor cells and host tissue. Methods: ITGA6 was knocked down and overexpressed in PC3 cells, and migration and morphology were measured in vitro. Proteins were assessed using immunostaining in PC3 and MDA-MB-231 cells (expression analysis only). Zebrafish xenografts tested loss and gain of function on angiogenesis and dissemination (ten or more labeled cells from the injection site). Cucurbitacin B (CuB), a pleiotropic compound reported to lower ITGA6, was tested to determine whether lowering ITGA6 lessens dissemination. Outcomes were reanalyzed with Fisher’s exact test, as were expression and outcome in TCGA cohorts (4273 tumors, nine types). Results: Knockdown reduced migration and dissemination in vivo. The host-supplied released extracellular domain displayed the strongest angiogenesis and dissemination, and a non-cleavable mutant reduced dissemination. CuB lowered ITGA6 protein levels and reduced dissemination. ITGA6 was expressed in all nine types, but bulk mRNA was not prognostic in the prostate or breast cohorts. Conclusions: In the PC3 model, ITGA6 and its cleavage regulate dissemination and angiogenesis in vivo. Blocking cleavage, most directly by antagonizing uPA, is a candidate strategy for testing in further models. Because CuB also acts on other pathways, its effects are consistent with, but do not prove, an ITGA6-mediated mechanism.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: